Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 11/20 | 0.61 |
| ▸ | HTR2B | P41595 | 9/20 | 0.61 |
| ▸ | MLNR | O43193 | 4/20 | 0.53 |
| ▸ | PNMT | P11086 | 2/20 | 0.52 |
| ▸ | DRD2 | P14416 | 3/20 | 0.45 |
| ▸ | DRD3 | P35462 | 3/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.43 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5458702 | 0.80 | DRD2 (0.59) | HTR2CHTR2BMLNRPNMTDRD2 | |
| SCHEMBL5455774 | 0.77 | HTR2C (1.00) | HTR2CHTR2BPNMTHTR6 | |
| SCHEMBL6324611 | 0.77 | GPR119 (0.46) | HTR2CDRD2DRD3HTR2AHTR6 | |
| SCHEMBL4033305 | 0.70 | PNMT (0.79) | HTR2CHTR2BMLNRPNMTDRD2 | |
| SCHEMBL6330764 | 0.70 | HTR2C (0.68) | HTR2CHTR2BPNMTHTR6 | |
| SCHEMBL6331549 | 0.69 | HTR2C (0.68) | HTR2CHTR2BPNMTHTR6 | |
| SCHEMBL5944522 | 0.69 | PNMT (1.00) | HTR2CHTR2BPNMTHTR6 | |
| Hydrochloric Acid SCHEMBL21753256 | 0.69 | PNMT (0.76) | HTR2CHTR2BMLNRPNMTDRD2 | |
| Hydrochloric Acid SCHEMBL6330901 | 0.68 | HTR2C (0.66) | HTR2CHTR2BPNMTHTR6 | |
| Hydrochloric Acid SCHEMBL5944489 | 0.68 | PNMT (0.97) | HTR2CHTR2BPNMTHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176759-A1 | 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment cns disorders | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-08-11 | — | — | US | claimed |
| EP-1456178-A1 | 7-SULFONYL-3-BENZAZEPINE DERIVATIVES AS MODULATORS OF THE DOPAMINE RECEPTOR AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 2004-09-15 | — | — | EP | claimed |
| WO-2003062205-A1 | 7-SULFONYL-3-BENZAZEPINE DERIVATIVES AS MODULATORS OF THE DOPAMINE RECEPTOR AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-07-31 | — | — | WO | claimed |
| US-20050176759-A1 | 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment cns disorders | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-08-11 | — | — | US | disclosed |
| EP-1456178-A1 | 7-SULFONYL-3-BENZAZEPINE DERIVATIVES AS MODULATORS OF THE DOPAMINE RECEPTOR AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003062205-A1 | 7-SULFONYL-3-BENZAZEPINE DERIVATIVES AS MODULATORS OF THE DOPAMINE RECEPTOR AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176759-A1 | 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment cns disorders | MPL, HTR2B, PDGFRB | HTR2C 49/4885HTR2B 2/4885MLNR 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.